Alnylam Pharma (DUL) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of CHF31.10B. The enterprise value is CHF39.88B.

Alnylam Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 13.74%.

The current PE Ratio of Alnylam Pharma is 67.3. Alnylam Pharma’s PEG ratio is -0.79.

In the last 12 months, Alnylam Pharma had revenue of 3.71B and earned 313.75M in profits. Earnings per share was 2.39.

In the last 12 months, operating cash flow was 712.90M and capital expenditures -71.56M, giving a free cash flow of 641.34M billion.

Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Alnylam Pharma upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).

Alnylam Pharma as a current ratio of 2.76, with Debt / Equity ratio of 118.38%

In the past 12 months, Alnylam Pharma has paid 9.40M in taxes.

Alnylam Pharma EV to EBITDA ratio is 92.81, with an EV/FCF ratio of 111.12.

Alnylam Pharma has CHF3.01B in cash and marketable securities with CHF1.27B in debt, giving a net cash position of CHF1.74B billion.

Gross margin is 80.89%, with operating margin of 13.51%, and net profit margin of 8.45%.

The average price target for Alnylam Pharma is CHF352.44, which is 11.43% higher than the current price. The consensus rating is Strong Buy